Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5714741 | 0.89 | HRH3 (0.49) | HRH3TACR3SMN1; SMN2HPGDGPR119 | |
| SCHEMBL5714872 | 0.89 | TACR3 (0.41) | HRH3PANK3TACR3HPGDGPR119 | |
| SCHEMBL5715200 | 0.88 | HRH3 (0.46) | HRH3HPGDALDH1A1GAAKMT2A | |
| SCHEMBL5715183 | 0.86 | SMN1; SMN2 (0.52) | HRH3SMN1; SMN2HPGDLMNAPOLB | |
| SCHEMBL5715090 | 0.86 | ALDH1A1 (0.47) | HRH3SMN1; SMN2HPGDGPR119ALDH1A1 | |
| SCHEMBL5904319 | 0.85 | KMT2A (0.41) | HRH3PANK3SMN1; SMN2HPGDGPR119 | |
| SCHEMBL5714905 | 0.85 | ALDH1A1 (0.39) | HRH3SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL26758723 | 0.84 | HRH3 (0.55) | HRH3PANK3TACR3SMN1; SMN2HPGD | |
| SCHEMBL5715004 | 0.83 | ALDH1A1 (0.38) | HRH3SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL5715736 | 0.82 | HRH3 (0.43) | HRH3PANK3TACR3SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636189-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111007-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| EP-1636189-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111007-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | LIPE, PNLIP, LIPC | HRH3 1098/4885PANK3 1247/4885TACR3 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.